Propofol Cardioprotection for Type II Diabetics

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

May 31, 2012

Study Completion Date

June 30, 2012

Conditions
Myocardial Injury
Interventions
DRUG

Propofol

Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).

DRUG

Propofol

Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.

Trial Locations (1)

V5Z 4E3

UBC Dept of Anesthesiology, Pharmacology & Therapeutics, Vancouver Acute Hospital, Vancouver

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University of British Columbia

OTHER

NCT00734383 - Propofol Cardioprotection for Type II Diabetics | Biotech Hunter | Biotech Hunter